NORWOOD, Mass., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a clinical stage oncology and obesity company, today provided a corporate update and reported financial results for the quarter ended June 30, 2025. "The second half of 2025 is shaping up to be impactful, with scheduled data readouts anticipated for all three of our clinical programs," said Yuval Cohen, Ph.D., Chief Executive Officer of Corbus. "We have been very pleased with t ...